继表皮生长因子受体(EGFR)基因突变和间变性淋巴瘤激酶(ALK)基因融合之后,Met基因激活突变和扩增被认为是非小细胞肺癌(NSCLC)下一个重要的驱动基因,它与肿瘤的增殖、侵袭、转移及血管生成密切相关,已成为靶向治疗领域研究的一大亮点。主要靶向治疗药物可分为抗HGF单克隆抗体、抗c-Met单克隆抗体和小分子抑制剂3类,并多已进入临床试验阶段。对作用于Met靶点的非小细胞肺癌治疗药物的研究进展进行综述。

Following the gene mutation of epidermal growth factor receptor (EGFR) and gene fusion of anaplastic lymphoma kinase (ALK), Met activating mutations and gene amplification are considered to be the next important driver gene of non-small-cell lung cancer (NSCLC), which is associated with tumor proliferation, invasion, metastasis, and angiogenesis. And this has become a major aspect of tumor targeted therapy research. The main targeted therapy drugs can be divided into anti-HGF monoclonal antibody, anti-c-Met monoclonal antibodies and small molecule inhibitors, and more of them have entered clinical trials. This review focuses on the latest research on c-Met and its targeted therapy drugs.